Bifogade filer
Qlucore Launches AI-based test for Acute Myeloid Leukemia
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software‑based test delivers multiple clinically relevant results from a single whole‑transcriptome sequencing run, including detection of samples with high levels of the important MECOM gene.
Acute Myeloid Leukemia is an aggressive blood cancer with an incidence that increases sharply with age, particularly in individuals over 60. In Europe, approximately 17,500 new AML cases are diagnosed each year, and the overall 5‑year survival rate is around 25 percent. The Qlucore Insights AML test analyzes whole transcriptomic sequencing data and provides:
- AI‑based classification of nine molecular AML subtypes
- Detection of more than 38 guideline‑mandated gene fusions
- Identification of novel gene fusions
- Quantification of MECOM gene expression levels
Risk stratification in AML relies on a combination of genetic markers and clinical parameters. Today, laboratories typically need to run several separate assays to obtain this information. By consolidating multiple analyses into one software‑based test, Qlucore enables laboratories to streamline workflows, reduce turnaround time, and improve cost efficiency.
The Qlucore Insights AML test is designed to fit seamlessly into standard laboratory processes and is easy to implement and operate, supporting both research teams and laboratories aiming to expand their molecular profiling capabilities.